Devita, Hellman, and Rosenberg's Cancer

LWBK1006-11 LWW-Govindan-Review November 24, 2011 11:21

126 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 11.14. Oblimersen has been shown to reduce the expression of Bcl-2 protein

using a technology known as antisense inhibition. Which of the following

statements most accurately defines oblimersen’s mechanism of action?

A. Oblimersen binds to its target mRNA that results in increased pro-

duction of Bcl-2 and the death of cancer cells.

B. A DNA/mRNA duplex is formed that activates TNF-, destroys the

bound mRNA, and decreases production of Bcl-2.

C. The binding of oblimersen to its target mRNA forms a duplex leading

to inhibition of translation of Bcl-2.

D. Oblimersen binds to its target mRNA that elicits the activity of RNase

H causing increased production of Bcl-2.

Question 11.15. You are about to see a 67-year-old female with newly diagnosed multiple

myeloma regarding initiation of chemotherapy. The patient’s daughter is

a health care worker and wants to know more about bortezomib therapy.

All of the following statements are correct EXCEPT:

A. Bortezomib is approved as single-agent therapy in newly diagnosed

multiple myeloma and given on days 1, 4, 8, and 11 of a 3-week cycle.

B. Thrombocytopenia and peripheral neuropathy were common ad-

verse events in clinical trials.

C. Bortezomib inhibits chymotrypsin-like activity at the 26S proteasome

leading to cell cycle arrest and apoptosis.

D. The phase III VISTA trial in patients with untreated multiple myeloma

showed the addition of bortezomib significantly improved response

rates in this setting.

Question 11.16. The azacytosine nucleosides possess complex dose-response characteris-

tics. Which of the following statements is correctly paired?

A. At high concentrations, dose-dependent reversal of DNA methylation

occurs.

B. At high concentrations, induction of terminal differentiation occurs

in some systems.

C. At lower concentrations, DNA damage and apoptosis become more

prominent.

D. At lower concentrations, inhibition of DNA methyltransferase activ-

ity predominates.

Question 11.17. Poly (ADP-ribose) polymerase (PARP) signals the presence of DNA dam-

age and facilitates DNA repair. Each of the following is a role of PARP

inhibitors in cancer treatment EXCEPT?

A. Chemotherapy and radiation sensitization

B. Serine/threonine kinase inhibition

C. Synthetic lethality with BRCA 1/2 mutations

D. Decreased hypoxia-inducible factor-1 function